%0 Journal Article
%T Identification of Metabolic Biomarkers Using Serial 18F每FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer
%A Gi Jeong Cheon
%A Hee Seung Kim
%A Hyun Hoon Chung
%A Junhwan Kim
%A Maria Lee
%A Tae Hun Kim
%A Yeon-koo Kang
%J Archive of "Translational Oncology".
%D 2017
%R 10.1016/j.tranon.2017.02.001
%X PURPOSE. To evaluate the prognostic value of metabolic parameters derived from serial 18F fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with advanced epithelial ovarian cancer (EOC). METHODS. Thirteen patients with advanced EOC who received surgical staging and adjuvant platinum-based combination chemotherapy were prospectively enrolled. 18F每FDG PET/CT was performed before and after the surgical staging, and after third cycle of chemotherapy. Tumor glucose metabolism at baseline and its change after operation and third cycle of chemotherapy such as changes of maximum standardized uptake values (忖SUVmax) via 18F每FDG PET/CT were measured, and assessed regarding their ability to predict recurrence. RESULTS. Median duration of progression-free survival (PFS) was 25 months (range, 13每34), and although optimal debulking was performed in 10 patients, 5 (38.5%) patients experienced recurrence. Univariate analyses showed significant associations between recurrence and low 忖SUVmax after surgical staging, and low SUVmax change after third cycle of chemotherapy. Multivariate analysis identified low 忖SUVmax after third cycle of chemotherapy as an independent risk factor for recurrence (P = .047, hazard ratio (HR) 16.375, 95% CI 1.041每257.536). Kaplan每Meier survival curves showed that PFS significantly differed in groups categorized based on 忖SUVmax after chemotherapy (P = .001, log-rank test). CONCLUSIONS. 18F每FDG PET/CT allows for prediction of treatment response by the level of FDG uptake in terms of SUV at baseline and after chemotherapy. The metabolic response measured as 忖SUVmax after third cycle of chemotherapy appears to be promising predictor of recurrence in patients with advanced EOC
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361859/